HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acrylamide

This article was originally published in The Rose Sheet

Executive Summary

Center for the Evaluation of Risks to Human Reproduction concludes there is "negligible concern" for adverse reproductive and developmental effects from exposure to acrylamide in the general population and there is "minimal concern" for acrylamide-induced heritable effects. There is "some concern" for adverse reproductive and developmental effects from occupational exposure to the chemical, the panel says. CERHR assessed the safety of acrylamide, an ingredient used in some cosmetics, during a meeting in May (1"The Rose Sheet" May 17, 2004, p. 9). The expert panel report from this evaluation will be available in about four weeks...

You may also be interested in...



CERHR Expert Panel To Review Acrylamide Safety

Human exposure to acrylamide through dermal contact with cosmetics and other consumer products is possible because the polyacrylamide used in these products may contain free acrylamide, the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction states in a 1draft report on the chemical

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS012178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel